

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	<b>Impression Healthcare Limited</b>
<b>ACN</b>	<b>93 096 635 246</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Alistair Glen <b>BLAKE</b>
<b>Date of last notice</b>	2 June 2017

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect and Direct
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Alistair Pty Ltd
<b>Date of change</b>	17 November 2017
<b>No. of securities held prior to change</b>	<b>Alistair Pty Ltd</b> (i) 15,185,841 ordinary fully paid shares (unlisted restricted)  (ii) 6,902,655 Class A Performance shares (unlisted restricted)  (iii) 6,902,655 Class B Performance shares (unlisted restricted)  <b>Alistair Glen Blake</b> (i) 147,157 Fully Paid Ordinary Shares
<b>Class</b>	(i) Fully Paid Ordinary Shares (ii) Class A Performance shares (iii) Class B Performance shares

---

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Number acquired</b>	<p>500,000 Fully Paid Ordinary Shares indirectly in the name of Alistair Pty Ltd as part of the Company's Non-Renounceable Rights Offer to all shareholders</p> <p>500,000 Options exercisable at 4 cents expiring 30 September 2020 indirectly in the name of Alistair Pty Ltd as part of the Company's Non-Renounceable Rights Offer to all shareholders</p>
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	<p>\$10,000 for ordinary shares</p> <p>Free attaching option as part of the Non-Renounceable Rights Offer</p>
<b>No. of securities held after change</b>	<p><b>Alistair Pty Ltd</b></p> <p>(i) 15,185,841 ordinary fully paid shares (unlisted restricted)</p> <p>(ii) 500,000 ordinary fully paid shares</p> <p>(iii) 6,902,655 Class A Performance shares (unlisted restricted)</p> <p>(iv) 6,902,655 Class B Performance shares (unlisted restricted)</p> <p>(v) 500,000 options exercisable at 4 cents expiry 30 September 2020</p>
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Shares and Options acquired as part of the Company's Non-Renounceable Rights Offer to all shareholders.

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest after change</b>	

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/a
<b>If prior written clearance was provided, on what date was this provided?</b>	N/a

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	<b>Impression Healthcare Limited</b>
<b>ACN</b>	<b>93 096 635 246</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Kelvin Robert <b>SMITH</b>
<b>Date of last notice</b>	24 May 2017

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Hudcon Investments Pty Ltd
<b>Date of change</b>	17 November 2017
<b>No. of securities held prior to change</b>	<b>Hudcon Investments Pty Ltd</b> (i) 1,939,712 ordinary fully paid shares (unlisted restricted)  (ii) 796,460 Class A Performance shares (unlisted restricted)  (iii) 796,460 Class B Performance shares (unlisted restricted)  (iv) 46,875 options  <b>Kelvin Smith &lt;Bantu Account&gt;</b> (i) 60,000 Fully Paid Ordinary Shares
<b>Class</b>	(i) Fully Paid Ordinary Shares (ii) Class A Performance shares (iii) Class B Performance shares (iv) Options exercise price \$0.128 expiry 31 Dec 2018 (unlisted restricted)

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Number acquired</b>	<p>406,250 Fully Paid Ordinary Shares in the name of Hudcon Investments Pty Ltd</p> <p>406,250 Options exercisable at 4 cents expiring 30 September 2020 indirectly in the name of Hudcon Investments Pty Ltd as part of the Company's Non-Renounceable Rights Offer to all shareholders</p> <p>22,500 Fully Paid Ordinary Shares in the name of Kelvin Smith &lt;Bantu Account&gt;</p> <p>22,500 Options exercisable at 4 cents expiring 30 September 2020 indirectly in the name of Kelvin Smith &lt;Bantu Account&gt; as part of the Company's Non-Renounceable Rights Offer to all shareholders</p>
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	<p>\$8,575 for ordinary shares</p> <p>Free attaching option as part of the Non-Renounceable Rights Offer</p>
<b>No. of securities held after change</b>	<p><b>Hudcon Investments Pty Ltd</b></p> <ul style="list-style-type: none"> <li>(i) 1,939,712 ordinary fully paid shares (unlisted restricted)</li> <li>(ii) 500,000 ordinary fully paid shares</li> <li>(iii) 796,460 Class A Performance shares (unlisted restricted)</li> <li>(iv) 796,460 Class B Performance shares (unlisted restricted)</li> <li>(v) 46,875 options</li> <li>(vi) 406,250 options exercisable at 4 cents expiry 30 September 2020</li> </ul> <p><b>Kelvin Smith &lt;Bantu Account&gt;</b></p> <ul style="list-style-type: none"> <li>(i) 82,500 Fully Paid Ordinary Shares</li> <li>(ii) 22,500 options exercisable at 4 cents expiry 30 September 2020</li> </ul>
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Shares and Options acquired as part of the Company's Non-Renounceable Rights Offer to all shareholders.

+ See chapter 19 for defined terms.

## **Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest after change</b>	

## **Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/a
<b>If prior written clearance was provided, on what date was this provided?</b>	N/a

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	<b>Impression Healthcare Limited</b>
<b>ACN</b>	<b>93 096 635 246</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	John Richard <b>WORSFOLD</b>
<b>Date of last notice</b>	20 October 2016

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
<b>Date of change</b>	17 November 2017
<b>No. of securities held prior to change</b>	(i) 1,752,212 ordinary fully paid shares (unlisted restricted)  (ii) 796,460 Class A Performance shares (unlisted restricted)  (iii) 796,460 Class B Performance shares (unlisted restricted)
<b>Class</b>	(i) Fully Paid Ordinary Shares (ii) Class A Performance shares (iii) Class B Performance shares

---

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Number acquired</b>	500,000 Fully Paid Ordinary Shares indirectly in the name of John Richard Worsfold as part of the Company's Non-Renounceable Rights Offer to all shareholders  500,000 Options exercisable at 4 cents expiring 30 September 2020 indirectly in the name of John Richard Worsfold as part of the Company's Non-Renounceable Rights Offer to all shareholders
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$10,000 for ordinary shares  Free attaching option as part of the Non-Renounceable Rights Offer
<b>No. of securities held after change</b>	(i) 1,752,212 ordinary fully paid shares (unlisted restricted)  (ii) 500,000 ordinary fully paid shares  (iii) 796,460 Class A Performance shares (unlisted restricted)  (iv) 796,460 Class B Performance shares (unlisted restricted)  (v) 500,000 options exercisable at 4 cents expiry 30 September 2020
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Shares and Options acquired as part of the Company's Non-Renounceable Rights Offer to all shareholders.

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/a
<b>If prior written clearance was provided, on what date was this provided?</b>	N/a

---

<sup>+</sup> See chapter 19 for defined terms.